Avantium provides Crystal16 to Sanofi-Aventis

Published: 6-Sep-2006

Amsterdam-based research company Avantium Technologies has made an agreement with Sanofi-Aventis for the deployment of its proprietary Crystal16 at all r&d centers of Sanofi-Aventis.


Amsterdam-based research company Avantium Technologies has made an agreement with Sanofi-Aventis for the deployment of its proprietary Crystal16 at all r&d centers of Sanofi-Aventis.

Sanofi-Aventis selected the Crystal16 for the enhancement of its crystallisation research capabilities, to increase the experimental throughput of its scientists and to be able to perform crystallisation experiments on a smaller scale.

The Crystal16 is a novel platform for performing parallel crystallisation experiments in 1-ml reactors. It can be used for a range of applications in pharmaceutical and chemical research, such as solubility measurements, improving the understanding of crystallisation processes and the generation of crystals for product characterisation.

You may also like